

# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/065,330 04/23/98 WALKER Α 2500.097US2 **EXAMINER** 020227 HM22/1108 MAJESTIC PARSONS SIEBERT & HSUE SAOUD.C **SUITE 1100 ART UNIT** PAPER NUMBER FOUR EMBARCADERO CENTER SAN FRANCISCO CA 94111-4106 1646 DATE MAILED: 11/08/99

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 





UNITED TES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	F	FIRST NAMED APPLICANT ATTORNEY DOCKET NO.		
09/065,330					
1			1		
					EXAMINER
				ART UNIT	PAPER NUMBER
					9
			j	DATE MAILED:	•

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below and/or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/Or Amino Acid Sequence Disclosures.

The communication filed on 04 October 1999 is not fully responsive to the communication mailed 10 June 1999 for the reason(s) set forth below and/or on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

The Raw Sequence Listing contains errors. Attached to this communication is a marked-up copy of the Raw Sequence Listing which details the errors in the Computer Readable Form of the Sequence Listing. It is believed that in addition to a new CRF, Applicant may also need to submit a new paper copy of the Sequence Listing. Applicant is reminded that a statement that the CRF and the paper copy are the same and include no new matter is also required (See attached Notice to Comply).

Since the response appears to be <u>bona fide</u>, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is required to complete the response within a time limit of one (1) month from the date of this letter or within the time remaining in the response period of the communication mailed10 June 1999, whichever is the longer. 37 CFR 1.135(c).

NO EXTENSION OF THIS TIME LIMIT MAY BE GRANTED UNDER EITHER 37 C.F.R. 1.136(a) OR (b), BUT THE STATUTORY PERIOD FOR RESPONSE SET IN THE COMMUNICATION MAILED 10 JUNE 1999 MAY BE EXTENDED UP TO A MAXIMUM OF SIX (6) MONTHS UNDER 37 CFR 1.136.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine Saoud, Ph.D., whose telephone number is (703) 305-7519. The examiner can normally be reached on Monday to Friday from 8AM to 3PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula Hutzell, can be reached on (703) 308-4310. The fax phone number for this Group is (703) 308-0294.

Official papers filed by fax should be directed to (703) 308-4227. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

November 5, 1999

Chusten Saoud

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29 May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other:

#### Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.

## Raw Sequence Listing Error Summary

### ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09 ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Wrapped Nucleics Please adjust your right margin to .3, as this will prevent "wrapping". The amino acid number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Wrapped Aminos Please adjust your right margin to .3, as this will prevent "wrapping". The rules require that a line not exceed 72 characters in length. This includes spaces. Incorrect Line Length The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers. Misaligned Amino Acid Numbering This file was not saved in ASCII (DOS) lext, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Non-ASCII \_ contain n's or Xaa's which represented more than one residue. As per the rules, each n or Xaa can only represent a single residue. \_\_ Variable Length Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing. A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) \_\_\_\_\_. Normally, Patentin would automatically generate this section from the Patentin ver. 2.0 "bug" previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. Sequence(s) \_\_\_\_ missing. If intentional, please use the following format for each skipped sequence: Skipped Sequences (i) SEQUENCE CHARACTERISTICS: (Do not insert any headings under "SEQUENCE CHARACTERISTICS") (OLD RULES) (xI) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s). Sequence(s) \_\_\_\_ missing. If intentional, please use the following format for each skipped sequence. Skipped Sequences <210> sequence ld number (NEW RULES) <400> sequence ld number 000 Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. Use of n's or Xaa's In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents. (NEW RULES) 11 \_\_\_\_ Use of <213>Organism Sequence(s) \_\_\_\_ are missing this mandatory field or its response. (NEW RULES) Sequence(s) \_\_\_\_ are missing the <220>Feature and associated headings. Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown" 12 \_\_\_\_ Use of <220>Feature Please explain source of genetic material in <220> to <223> section. (NEW RULES) (Sec. 1.823 of new Rules) (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). \_\_ Patentin ver. 2.0 "bug" Instead, please use "File Manager" or any other means to copy file to floppy disk. AKS-Biotechnology Systems Branch- 5/15/99